Intervention Protocol

You have free access to this content

Perampanel add-on for drug-resistant partial epilepsy

  1. Jianyi Huang1,
  2. Yousheng Xiao1,
  3. Man Luo1,
  4. Hongye Luo2,
  5. Jin Wang1,*

Editorial Group: Cochrane Epilepsy Group

Published Online: 6 FEB 2014

Assessed as up-to-date: 22 JAN 2014

DOI: 10.1002/14651858.CD010961


How to Cite

Huang J, Xiao Y, Luo M, Luo H, Wang J. Perampanel add-on for drug-resistant partial epilepsy (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010961. DOI: 10.1002/14651858.CD010961.

Author Information

  1. 1

    The First Affiliated Hospital, Guangxi Medical University, Department of Neurology, Nanning, Guangxi, China

  2. 2

    Guangxi Medical University, Department of Epidemiology & Statistics, Nanning, Guangxi, China

*Jin Wang, Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Lu, Nanning, Guangxi, 530021, China. wangjin72@126.com.

Publication History

  1. Publication Status: New
  2. Published Online: 6 FEB 2014

SEARCH

References

Additional references

Ceolin 2012
  • Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochemistry International 2012;61(4):517-22. [PUBMED: 22433907]
Franco 2013
  • Franco V, Crema F, Iudice A, Zaccara G, Grillo E. Novel treatment options for epilepsy: focus on perampanel. Pharmacological Research 2013;70(1):35-40. [PUBMED: 23287426]
French 2012
  • French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79(6):589-96. [PUBMED: 22843280]
French 2013
Hanada 2011
Hesdorffer 2011
  • Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology 2011;76(1):23-7. [PUBMED: 21205691]
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kirkham 2010
  • Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (Clinical research ed.) 2010;340:c365. [PUBMED: 20156912]
Krauss 2012
  • Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78(18):1408-15. [PUBMED: 22517103]
Krauss 2012a
Kwan 2010
Lefebvre 2011
  • Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Ngugi 2011
  • Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011;77(10):1005-12. [PUBMED: 21893672]
Owen 2013
  • Owen RT. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures. Drugs of Today (Barcelona, Spain: 1998) 2013;49(1):23-31. [PUBMED: 23362493]
Plosker 2012
Rektor 2013
  • Rektor I. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opinion on Pharmacotherapy 2013;14(2):225-35. [PUBMED: 23259931]
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rogawski 2011
Rogawski 2013
Schmidt 2002
Schuele 2008
Shvarts 2013
  • Shvarts V, Chung S. Perampanel: newly approved, novel antiepileptic medication for partial-onset seizures. Expert Review of Neurotherapeutics 2013;13(2):131-4. [PUBMED: 23368799]